A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM326 Injection in the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 05 Jan 2023
At a glance
- Drugs CM 326 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors KeyMed Biosciences
- 05 Jan 2023 New trial record